Product overview with focus on rare and special diseases.
AOP Orphan's focus is on rare and special diseases. The portfolio comprises products in the following therapeutic areas: HematoOncology, Cardiology & Pulmonology, Neurology and Metabolic Disorders and Intensive Care. AOP Orphan’s strategic goal is to constantly deliver new treatment options with respect to rare and special diseases.
Anagrelide AOP is indicated in Essential Thrombocythemia for the reduction of elevated platelet counts and associated clinical symptoms in at high risk patients
BESREMi® is indicated as monotherapy in adults for the treatment of Polycythaemia Vera without symptomatic splenomegaly.
Canemes® is indicated for the treatment of nauseas and vomiting in adults who do not adequately respond to other anti-emetic treatment options.
Thromboreductin® is indicated for the reduction of elevated platelet counts and associated clinical symptoms in at high risk essential thrombocythemia patients